Adnan Majid, MD
Pulmonary Disease · Boston, MANPI 1790797561
Payments from drug & device makers
Across 568 payments — averaging $1386.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galvanize Therapeutics, Inc$236K
- Olympus Latin America, Inc.$100K
- Pneumrx, Inc$80K
- Pulmonx Corporation$65K
- Pinnacle Biologics, Inc$62K
- Olympus Corporation Of The Americas$58K
- plus $186K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galvanize Therapeutics, Inc | 14 | $236,302 |
| Olympus Latin America, Inc. | 164 | $99,716 |
| Pneumrx, Inc | 2 | $79,889 |
| Pulmonx Corporation | 37 | $65,343 |
| Pinnacle Biologics, Inc | 65 | $61,643 |
| Olympus Corporation Of The Americas | 82 | $58,455 |
| Gyrus ACMI, Inc. | 8 | $52,837 |
| Boston Scientific | 27 | $21,247 |
| US Endoscopy | 4 | $20,800 |
| Cook Incorporated | 8 | $20,464 |
| Intuitive Surgical | 44 | $14,842 |
| Johnson & Johnson | 14 | $12,488 |
| BD | 1 | $8,671 |
| Bard Peripheral Vascular, Inc. | 2 | $6,671 |
| Olympus America Inc. | 12 | $6,367 |
| Medtronic | 21 | $6,207 |
| Olympus Medical Systems Corporation | 5 | $5,538 |
| Spiration, Inc. | 8 | $3,628 |
| Olympus Corporation | 7 | $1,463 |
| Veran Medical Technologies, Inc. | 4 | $1,408 |
| Steris Corporation | 10 | $895 |
| Janssen Research & Development, LLC | 1 | $675 |
| Noah Medical Corporation | 5 | $532 |
| ERBE USA Inc | 5 | $521 |
| Serpex Medical Inc | 1 | $172 |
| Covidien LP | 3 | $154 |
| Philips North America LLC | 1 | $127 |
| AstraZeneca | 1 | $125 |
| Cook Medical LLC | 2 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Verona Pharma, Inc. | 1 | $82 |
| Rocket Medical LLC | 1 | $79 |
| Lumenis, Inc | 1 | $59 |
| Pfizer | 1 | $28 |
| Ambu Inc. | 1 | $24 |
| Merck | 1 | $18 |
How this compares
$787,688 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Boston
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Gary HunninghakeBoston$1.5M
- Peter LacameraBoston$1.3M
- Barry SheaBoston$1M
- Isabel NeuringerBoston$817K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.